-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
Recently, the Chinese drug clinical trial registration and information disclosure platform showed that Novo Nordisk has launched a trial in China to study how NNC0174-0833 (cagrilintide) can play a role in normal weight, overweight or obese Chinese population
.
Cagrilintide is an amylin analogue cagrilintide under development by Novo Nordisk.
Screenshot source: Chinadrugtrials
Cagrilintide is a long-acting amylin analog with a half-life of about 7-8 days
.
Amylin (amylin) is another hormone related to hunger and satiety besides the GLP-1 signaling pathway
This time, Novo Nordisk initiated a pharmacokinetic study of a single subcutaneous injection of cagrilintide in Chinese male subjects with normal weight, overweight or obesity
.
The purpose of the study is to observe the effects of the study drug in the participants' bodies and how they are removed from their bodies
According to a study published in the journal The Lancet in April this year, the combination therapy of cagrilintide and smeglutide was shown to be well tolerated and acceptable safety in a phase 1b clinical study
.
In this trial, 96 subjects were randomly assigned to the cagrilintide group (0.
The results showed that at the 20th week, the average weight loss percentages (-15.
7%, -17.
1%) of the cagrilintide 1.
2mg and 2.
4mg groups were greater than those of the placebo group (-9.
8%)
.
The estimated treatment differences between the cagrilintide 1.
According to statistics from the World Health Organization, the number of obese patients worldwide has nearly tripled since 1975, and more than 1.
9 billion adults are overweight
.
Obesity is associated with an increased risk of various diseases such as type 2 diabetes, cancer, and cardiovascular disease.
Reference materials:
[1] Drug clinical trial registration and information disclosure platform.
